Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.65% to $604.62 Wednesday, on what proved to be an all-around dismal ...

ProShare Advisors LLC increased its stake in Regeneron Pharmaceuticals by a hefty 21.7% in Q4, now owning 146,135 shares ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...